SC
Steven Cohen (Point72) disclosed increased in HALOZYME THERAPEUTICS INC
Steven Cohen (Point72) filed a 13F change in HALOZYME THERAPEUTICS INC (40637HAF6) on 2026-05-15, covering period end 2026-03-31.
Action
Increased
Capital
$6,612,981 reported value
Institutional 13F Signals1 evidence source
Why it matters
This signal is anchored to the SEC filing date while retaining the underlying 13F period end.